Richard Zimmerman

Dr. Richard Zimmerman

orcid

Research Focus & Metrics

Academic Career Length

38Years (1989-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 November 2013 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
SOSuzanne E. Ohmit
Suzanne E. Ohmit
MTMark G. Thompson
Mark G. Thompson
JPJoshua G. Petrie
Joshua G. Petrie
STSwathi N. Thaker
Swathi N. Thaker
MJMichael L. Jackson
Michael L. Jackson
AMArnold S. Monto
Arnold S. Monto
Background. Each year, the US Influenza Vaccine Effectiveness Network examines the effectiveness of influenza vaccines in preventing medically attended acute respiratory illnesses caused by influenza. Methods. Patients with acute respiratory illnesses of ≤7 days’ duration were enrolled at ambulatory care facilities in 5 communities. Specimens were collected and tested for influenza by real-time reverse-transcriptase polymerase chain reaction. Receipt of influenza vaccine was defined based on documented evidence of vaccination in medical records or immunization registries. Vaccine effectiveness was estimated in adjusted logistic regression models by comparing the vaccination coverage in those who tested positive for influenza with those who tested negative. Results. The 2011–2012 season was mild and peaked late, with circulation of both type A viruses and both lineages of type B. Overall adjusted vaccine effectiveness was 47% (95% confidence interval [CI], 36–56) in preventing medically attended influenza; vaccine effectiveness was 65% (95% CI, 44–79) against type A (H1N1) pdm09 but only 39% (95% CI, 23–52) against type A (H3N2). Estimates of vaccine effectiveness against both type B lineages were similar (overall, 58%; 95% CI, 35–73). An apparent negative effect of prior year vaccination on current year effectiveness estimates was noted, particularly for A (H3N2) outcomes. Conclusions. Vaccine effectiveness in the 2011–2012 season was modest overall, with lower effectiveness against the predominant A (H3N2) virus. This may be related to antigenic drift, but past history of vaccination might also play a role.

4 October 2016 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
RZRichard Zimmerman
Richard Zimmerman
MNMary Patricia Nowalk
Mary Patricia Nowalk
JCJessie Chung
Jessie Chung
MJMichael L. Jackson
Michael L. Jackson
LJLisa A. Jackson
Lisa A. Jackson
BFBrendan Flannery
Brendan Flannery
Circulating A/H3N2 influenza viruses drifted significantly after strain selection for the 2014–2015 vaccines. Also in 2014–2015, the Advisory Committee on Immunization Practices recommended preferential use of live attenuated influenza vaccine (LAIV) over inactivated influenza vaccine (IIV) among children aged 2–8 years. Vaccine effectiveness (VE) across age groups and vaccine types was examined among outpatients with acute respiratory illness at 5 US sites using a test-negative design, that compared the odds of vaccination among reverse transcription polymerase chain reaction–confirmed influenza positives and negatives. Of 9311 enrollees with complete data, 7078 (76%) were influenza negative, 1840 (19.8%) were positive for influenza A (A/H3N2, n = 1817), and 395 (4.2%) were positive for influenza B (B/Yamagata, n = 340). The overall adjusted VE was 19% (95% confidence interval [CI], 10% to 27%) and was statistically significant in all age strata except those aged 18–64 years. The adjusted VE of 6% (95%CI, −5% to 17%) against A/H3N2-associated illness was not statistically significant, unlike VE for influenza B/Yamagata, which was 55% (95%CI, 43% to 65%). Among those aged 2–8 years, VE against A/H3N2 was 15% (95%CI, −16% to 38%) for IIV and −3% (CI, −50% to 29%) for LAIV; VE against B/Yamagata was 40% (95%CI, −20% to 70%) for IIV and 74% (95%CI, 25% to 91%) for LAIV. The 2014–2015 influenza vaccines offered little protection against the predominant influenza A/H3N2 virus but were effective against influenza B. Preferential use of LAIV among young children was not supported.

18 November 2014 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
HMHuong Q. McLean
Huong Q. McLean
MTMark G. Thompson
Mark G. Thompson
MSMaria E. Sundaram
Maria E. Sundaram
BKBurney A. Kieke
Burney A. Kieke
MGManjusha Gaglani
Manjusha Gaglani
EBEdward A. Belongia
Edward A. Belongia
Background. During the 2012–2013 influenza season, there was cocirculation of influenza A(H3N2) and 2 influenza B lineage viruses in the United States. Methods. Patients with acute cough illness for ≤7 days were prospectively enrolled and had swab samples obtained at outpatient clinics in 5 states. Influenza vaccination dates were confirmed by medical records. The vaccine effectiveness (VE) was estimated as [100% × (1 − adjusted odds ratio)] for vaccination in cases versus test-negative controls. Results. Influenza was detected in 2307 of 6452 patients (36%); 1292 (56%) had influenza A(H3N2), 582 (25%) had influenza B/Yamagata, and 303 (13%) had influenza B/Victoria. VE was 49% (95% confidence interval [CI], 43%–55%) overall, 39% (95% CI, 29%–47%) against influenza A(H3N2), 66% (95% CI, 58%–73%) against influenza B/Yamagata (vaccine lineage), and 51% (95% CI, 36%–63%) against influenza B/Victoria. VE against influenza A(H3N2) was highest among persons aged 50–64 years (52%; 95% CI, 33%–65%) and persons aged 6 months–8 years (51%; 95% CI, 32%–64%) and lowest among persons aged ≥65 years (11%; 95% CI, −41% to 43%). In younger age groups, there was evidence of residual protection from receipt of the 2011–2012 vaccine 1 year earlier. Conclusions. The 2012–2013 vaccines were moderately effective in most age groups. Cross-lineage protection and residual effects from prior vaccination were observed and warrant further investigation.

1 March 2003 in Vaccine
Verified
Journal Article
Closed access
RZRichard Zimmerman
Richard Zimmerman
MRMahlon Raymund
Mahlon Raymund
JJJanine E Janosky
Janine E Janosky
MNMary Patricia Nowalk
Mary Patricia Nowalk
MFMichael J Fine
Michael J Fine

29 June 2005 in Journal of Medical Internet Research
Verified
Journal Article
Open access
RZRichard Zimmerman
Richard Zimmerman
RWRobert M Wolfe
Robert M Wolfe
DFDwight E Fox
Dwight E Fox
JFJake R Fox
Jake R Fox
MNMary Patricia Nowalk
Mary Patricia Nowalk
LSLisa K Sharp
Lisa K Sharp
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet

10 December 2001 in Archives of internal medicine (1960)
Verified
Journal Article
Open access
PDF file
KNKristin L. Nichol
Kristin L. Nichol
RZRichard Zimmerman
Richard Zimmerman
INFLUENZA AND pneumococcal diseases cause hundreds of thousands of hospitalizations and tens of thousands of deaths each year.1,2 In fact, these 2 vaccine-preventable diseases are responsible for more deaths than all other vaccine-preventable diseases combined, with more than 90% of these deaths occurring among the elderly and others with high-risk medical conditions.3